N-[5-(aminomethyl)pyridin-2-yl]acetamide | 1249669-77-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[5-(aminomethyl)pyridin-2-yl]acetamide
• CAS: 1249669-77-9
• 化学式: C₈H₁₁N₃O
• mdl: MFCD16737552
• 分子量: 165.195
• InChiKey: URQYQEXXCUXLPM-UHFFFAOYSA-N

物化性质

• 沸点：
  417.2±35.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[5-(aminomethyl)pyridin-2-yl]acetamide 、 喹喔啉-6-甲醛 在 N-(benzyloxy)-N-(pivaloyloxy)-4-(trifluoromethyl)benzamide 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 40.0h， 生成 N-(5-(2-(quinoxalin-6-yl)ethyl)pyridin-2-yl)acetamide
  参考文献：
  名称：

  通过氮删除的 C−C 偶联：在库合成中的应用

  摘要：

  采用（杂）芳香醛和（杂）芳基甲基胺作为结构单元，异头酰胺作为试剂的还原胺化-“氮缺失”反应序列用于化合物库的平行合成。该方法可以访问与早期药物发现计划相关的超过 50 万种化合物的化学空间。

  DOI：

  10.1002/chem.202203470

文献信息

• [EN] INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS INDAZOLE COMME ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009134666A1

  公开（公告）日：2009-11-05

  Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  揭示了吲唑烯化合物，其作为CCR1活性拮抗剂是有用的，因此可用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫疾病，如类风湿性关节炎和多发性硬化症。还披露了包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• Novel 2-pyridinecarboxamide derivatives
  申请人：Mitsuya Morihiro

  公开号：US20060258701A1

  公开（公告）日：2006-11-16

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，具有激活葡萄糖激酶的效果，并可用作糖尿病治疗剂，其化学式表示为（I）：[其中X1表示氮原子、硫原子、氧原子或类似物；R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物；D表示氧原子或硫原子；R和R3相同或不同，分别表示氢原子、低碳基或类似物；式（II）表示可选取代的5-至7-成员杂芳基团或类似物；式（III）表示单环或双环杂芳基团]或其药学上可接受的盐。
• NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES
  申请人：MITSUYA MORIHIRO

  公开号：US20100041660A1

  公开（公告）日：2010-02-18

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R 2 and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有葡萄糖激酶激活作用并且可用作糖尿病治疗剂的化合物，其化学式为（I）：[其中X1代表氮原子、硫原子、氧原子或类似物；R1代表6到10个成员的芳基基团、5到7个成员的杂芳基团或类似物；D代表氧原子或硫原子；R2和R3相同或不同，每个代表氢原子、低碳基团或类似物；化学式（II）代表可选取代的5到7个成员的杂芳基团或类似物；化学式（III）代表单环或双环杂芳基团]或其药学上可接受的盐。
• Azaindazole Compounds As CCR1 Receptor Antagonists
  申请人：COOK Brian Nicholas

  公开号：US20100093724A1

  公开（公告）日：2010-04-15

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

  本发明涉及式(I)化合物，其可用于治疗多种疾病和障碍，这些疾病和障碍是通过CCR1的活性介导或维持的，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。同时，本发明还涉及制备方法和使用方法。
• Indazole Compounds As CCR1 Receptor Antagonists
  申请人：KUZMICH Daniel

  公开号：US20110294808A1

  公开（公告）日：2011-12-01

  Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  公开了一种吲唑化合物，可用作CCR1活性的拮抗剂，因此可用于治疗通过CCR1活性介导或维持的各种疾病和障碍，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。还公开了包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。